Topic is suspended
| Status | Suspended |
| Decision | Selected |
| Process | TA |
| ID number | 1496 |
Project Team
| Project lead | Emily Richards |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2021 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant. For information, the company has advised it has paused its effort to pursue a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 29 January 2021 | Suspended. Topic is suspended |
| 13 May 2019 (10:00) | Scoping workshop (Manchester) |
| 20 March 2019 - 17 April 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 26 June 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual